Investigation Date: Mar 8, 2026
This report is 5 days old
Market data and risk factors may have changed since this investigation was generated.
Founder shares were acquired at $0.001-$10 versus retail's $35.73 price, creating 3,500x to 35x cost basis advantages for insiders. What This Means: Early investors and management have massive unrealized gains while retail investors need quantum computing commercialization to justify current valuations.
INSIDER COST BASIS BREAKDOWN
PIPE INVESTOR TERMS: Institutional PIPE investors received shares at $10 per share in the original SPAC transaction. At the current price of $35.73, PIPE investors are sitting on 257% unrealized gains.
WARRANT DILUTION: The SPAC structure included warrants exercisable at $11.50. With approximately 23 million warrants outstanding, full exercise would generate $264.5 million but dilute existing shareholders by roughly 18%.
UNDERWRITER COMPENSATION: Goldman Sachs and other underwriters received approximately $35.73 million in fees plus additional warrant coverage, representing roughly 2.3% of the total transaction value.
LOCK-UP ANALYSIS: Most insider lock-up periods expired in April 2022. Post-lock-up, the stock declined from peaks near $35 to lows around $2 before the recent quantum computing sector rally drove it back to current levels.
RELATED PARTY TRANSACTIONS: The most recent DEF 14A shows standard director compensation and no unusual related party transactions, though several board members have significant equity stakes from the original SPAC transaction.
Management claims about quantum advantage and commercial partnerships lack independent validation, while revenue projections consistently miss actual results. What This Means: Investors are betting on technology claims that remain largely unverified by independent sources or meaningful commercial contracts.
"Industry-leading quantum computing performance and fidelity"
Company cites internal benchmarks and IBM quantum network participation. However, independent peer-reviewed studies comparing IonQ's systems to competitors like Google, IBM, or Rigetti are limited. Most performance claims come from company-sponsored research or internal measurements.
Unverified — Performance claims lack independent third-party validation
"Strategic partnerships with Amazon, Microsoft, and Google Cloud"
SEC filings confirm cloud access agreements allowing customers to use IonQ systems through AWS Braket, Azure Quantum, and Google Cloud. However, these are technology integration partnerships, not revenue-generating contracts. The partnerships provide cloud access but don't guarantee minimum revenue commitments.
Exaggerated — Real partnerships exist but are access agreements, not commercial contracts
"$13.4 million contracted bookings for 2024"
Most recent 10-Q shows actual revenue of $6.1 million for Q3 2024, with full-year 2024 revenue trending below the contracted bookings projection. Historical pattern shows bookings often don't convert to recognized revenue in the same period due to milestone-based recognition.
Contradicted — Actual revenue consistently trails booking projections
"Addressing $850 billion quantum computing market by 2040"
This figure traces to third-party consulting firm projections (BCG, McKinsey studies). However, these studies assume widespread quantum advantage across multiple industries by 2040, which remains speculative given current technological limitations.
Unverified — Market size projections based on optimistic scenarios not yet proven feasible
PATENT PORTFOLIO ANALYSIS: IonQ holds approximately 600 patent applications and 100+ granted patents in quantum computing. However, many patents cover incremental improvements rather than breakthrough quantum algorithms. Core quantum computing principles remain largely unpatentable, limiting competitive moats.
Clean legal structure with no active litigation, but auditors expressed substantial doubt about going concern in 2023 due to cash burn rates. What This Means: No immediate legal threats, but the company's survival depends on continued access to capital markets.
This going concern qualification was removed in 2024 filings after the company raised additional capital, but the underlying cash burn dynamics remain challenging.
AUDITOR ANALYSIS: Ernst & Young LLP serves as the company's independent auditor. No auditor changes or material weaknesses in internal controls have been reported. EY is a Big Four accounting firm, providing credibility to financial statements.
REGULATORY COMPLIANCE: No SEC enforcement actions, FDA issues, or other regulatory sanctions identified. As a technology company without regulated products, IonQ faces minimal direct regulatory oversight compared to biotech or financial services companies.
SEC COMMENT LETTERS: Review of SEC correspondence shows routine comment letters related to revenue recognition timing and partnership accounting, but no material concerns flagged by regulators.
CORPORATE STRUCTURE: Standard Delaware C-Corporation structure with single class of common stock. No complex variable interest entities or unusual offshore structures that could create governance risks.
LITIGATION EXPOSURE: No material pending litigation disclosed in most recent 10-K. Standard intellectual property disputes are possible in the quantum computing space but none currently active against IonQ.
RESTATEMENT HISTORY: No financial restatements identified in SEC filings since going public. Clean accounting history with no material weakness disclosures.
Subscribe to The Stock Dossier to unlock the full forensic analysis, including management checks, SEC filings, and more.
$9.99/month. Cancel anytime.
Want to run your own forensic investigation?
Get Started with The Stock Dossier